Hematologic Oncology | Specialty

The OncLive Hematology Oncology condition center page is a comprehensive resource for clinical news and expert insights on various hematologic malignancies, including leukemias, lymphomas, myeloproliferative neoplasms, multiple myeloma, and much more. This section features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in hematologic cancers.

Managing Venetoclax-Associated Toxicity in AML

January 28th 2020

Treatment Options After Second-Line Relapse

January 28th 2020

Venetoclax-Based Regimens for Unfit Patients with AML

January 28th 2020

Relapsed/Refractory Treatment: The MAGNIFY Regimen

January 28th 2020

Determining Second-Line Therapy in FL

January 28th 2020

Hypomethylating Agents for AML

January 28th 2020

QUAZAR: Oral Azacitidine Maintenance in AML

January 28th 2020

Phase III GALLIUM Results and Maintenance Therapy

January 28th 2020

Immunochemotherapy Decision Factors

January 28th 2020

Decision Making on Consolidation Therapy for AML

January 28th 2020

Assessment of Fitness for AML Induction Chemotherapy

January 28th 2020

When to Initiate Therapy for Follicular Lymphoma

January 28th 2020

The Importance of Risk Assessment

January 28th 2020

AML Induction Strategy and Molecular Testing

January 28th 2020

Molecular Testing for AML

January 28th 2020

Differential Diagnosis and Staging of Follicular Lymphoma

January 28th 2020

Dr. Vusirikala on Ongoing Research With Blinatumomab in ALL

January 28th 2020

Madhuri Vusirikala, MD, professor of internal medicine in the Division of Hematology/Oncology at the Harold C. Simmons Comprehensive Cancer Center of UT Southwestern Medical Center, discusses ongoing research with blinatumomab (Blincyto) in acute lymphoblastic leukemia (ALL).

Long-Term Data, Novel Regimens Showcase Progress in ALL

January 27th 2020

Madhuri Vusirikala, MD, discusses recent changes in the treatment paradigm of acute lymphoblastic leukemia, based on data from the 2019 ASH Annual Meeting.

Dr. Diefenbach on Polatuzumab Vedotin Plus Obinutuzumab and Lenalidomide in FL

January 27th 2020

Catherine M. Diefenbach, MD, discusses polatuzumab vedotin (Polivy) plus obinutuzumab (Gazyva) and lenalidomide (Revlimid) in patients with follicular lymphoma.

Novel Strategies and Agents Emerge in AML Paradigm

January 25th 2020

Rebecca L. Olin, MD, MSCE, sheds light on the pivotal progress made in acute myeloid leukemia treatment in recent years.